XyloCor Therapeutics

XyloCor Therapeutics is a biopharmaceutical company developing gene therapies for advanced coronary artery disease, focused on improving the lives of patients with cardiovascular disease through proprietary gene therapy technologies. The company's lead candidate, XC001, is designed for patients with refractory angina who have no remaining treatment options, stimulating the formation of new coronary blood vessels to serve areas of the heart not receiving adequate blood supply through therapeutic angiogenesis. XC001 is enabled by proprietary gene therapy technologies originating from Weill Cornell Medical College. The company's secondary product candidate, XC002, is in the discovery stage and involves the regeneration of cardiac tissue for patients who have suffered heart attack-related cardiac tissue damage. XyloCor's approach addresses significant unmet clinical needs in cardiovascular disease by leveraging gene therapy to promote vascularization and tissue repair in the heart, targeting patient populations with limited conventional therapeutic options. Founded in 2013 and headquartered in Newtown Square, Pennsylvania, XyloCor Therapeutics has raised $110.9M in Series B funding from investors including Fountain Healthcare Partners, Longwood Fund, Lumira Ventures, Sofinnova Investments, Life Sciences Partners, Jeito, and EQT.